India Approves First Dengue Vaccine QDENGA

DCGI granted market authorisation to QDENGA, making it India’s first approved dengue vaccine. The vaccine is meant for prevention of dengue in individuals aged 4 to 60 years.

India approved its first dengue vaccine, QDENGA, after clearance from the Drug Controller General of India. The vaccine has been developed by Takeda Biopharmaceuticals India and is intended for individuals aged 4 to 60 years. QDENGA is a tetravalent dengue vaccine, meaning it is designed to protect against all four dengue virus serotypes. Dengue is a major mosquito-borne disease in India and creates a recurring public health burden. The approval is significant for health policy, vaccine regulation and disease prevention.